Invesco Ltd. Kronos Bio, Inc. Transaction History

Invesco Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.34 - $2.62 $69,220 - $135,341	-51,657 Reduced 83.12%	10,489 $15,000
Q4 2022 Feb 13, 2023	SELL	$1.44 - $3.44 $2,049 - $4,895	-1,423 Reduced 2.24%	62,146 $100,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $9,838 - $16,300	-2,937 Reduced 4.42%	63,569 $213,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $28,151 - $67,852	9,023 Added 15.7%	66,506 $243,000
Q1 2022 May 16, 2022	BUY	$6.26 - $14.42 $274,156 - $631,523	43,795 Added 319.95%	57,483 $416,000
Q4 2021 Feb 14, 2022	SELL	$11.35 - $21.18 $1,940 - $3,621	-171 Reduced 1.23%	13,688 $186,000
Q3 2021 Nov 15, 2021	BUY	$18.17 - $24.7 $39,229 - $53,327	2,159 Added 18.45%	13,859 $290,000
Q2 2021 Aug 17, 2021	SELL	$20.08 - $29.02 $4.69 Million - $6.78 Million	-233,503 Reduced 95.23%	11,700 $279,000
Q1 2021 May 17, 2021	SELL	$27.0 - $32.48 $3.58 Million - $4.31 Million	-132,553 Reduced 35.09%	245,203 $7.18 Million
Q4 2020 Feb 16, 2021	BUY	$26.68 - $38.23 $10.1 Million - $14.4 Million	377,756 New	377,756 $11.3 Million

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.